P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: Association between disease onset and proline genotype

Pathobiology

Volumn 78, Issue 4, 2011, Pages 193-200

  Rogler, Anja ^a   Rogenhofer, Michael ^a   Borchardt, Albert ^b   Lunz, Jens Claudio ^c   Knoell, Antje ^a   Hofstaedter, Ferdinand ^d   Tannapfel, Andrea ^e   Wieland, Wolf ^d   Hartmann, Arndt ^a   Stoehr, Robert ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Medical Center Roethelheimpark   (Germany)

^c Group Practice for General Medicine   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

p53; Prostate cancer; Restriction fragment length polymorphism; Single nucleotide polymorphism

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CAUCASIAN; CELL STRESS; CODON; COHORT ANALYSIS; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; WART VIRUS; WILD TYPE;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CASE-CONTROL STUDIES; GENE FREQUENCY; GENES, P53; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

HUMAN PAPILLOMAVIRUS;

EID: 79960709555     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000326767     Document Type: Article

References (37)

1. Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
2. RKI and GEKID: Cancer in Germany 2005/2006: Incidences and Trends 05/06, pp 72-75. http://www.rki.de/nn-1219822/EN/Content/Health-Reporting/ GBEDownloadsB/KID2010,templateId=raw,property=publicationFile.pdf/KID2010.pdf.
3. Brooks CL, Gu W: p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006; 21: 307-315. (Pubitemid 43163526)
4. Meek DW: Tumor suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009; 9: 714-723.
5. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331. (Pubitemid 27131374)
6. Agell L, Hernandez S, de Muga S, Lorente JA, Juanpere N, Esgueva R, Serrano S, Gelabert A, Lloreta J: KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. Mod Pathol 2008; 21: 1470-1478.
7. Ara S, Lee PS, Hansen MF, Saya H: Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990; 18: 4961. (Pubitemid 20280142)
8. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19: 1092-1100. (Pubitemid 29046852)
9. Murphy ME, Leu JI, George DL: p53 moves to mitochondria: a turn on the path to apoptosis. Cell Cycle 2004; 3: 836-839. (Pubitemid 40179452)
10. Murphy ME: Polymorphic variants in the p53 pathway. Cell Death Differ 2006; 13: 916-920.
11. Whibley C, Pharoa PDP, Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9: 95-107.
12. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L: Role of a p53 polymorphism in the development of human papilloma virus-associated cancer. Nature 1998; 393: 229-234. (Pubitemid 28261713)
13. Henner D, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM: Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 2001; 49: 263-266. (Pubitemid 33117001)
14. Wu HC, Chang CH, Chen HY, Tsai FJ, Tsai JJP, Chen WC: p53 gene codon 72 polymorphism but not tumor necrosis factor-gene is associated with prostate cancer. Urol Int 2004; 73: 41-46.
15. Zhu Y, Wang J, He Q, Zhang JQ: Association of p53 codon 72 polymorphism with prostate cancer: a meta-analysis. Mol Biol Rep 2011; 38: 1603-1607.
16. Epstein JI, Algaba F, Allsbrook WC, Bastacky S, Boccon-Gibod L, De Marzo AM, Egevad L, Furusato M, Hamper UM, Helpap B, Humphrey PA, Iczkowski KA, Lopez-Beltran A, Montironi R, Rubin MA, Sakr WA, Samaratunga H, Parkin DM: Tumours of the prostate; in Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, IARC, 2004, pp 159-216.
17. Sobin LH, Wittekind C: TNM classification of malignant tumors. New York, Wiley, 2002.
18. Faur N, Araud L, Laroche-Clary A, Kanno J, Toutain J, Yamori T, Robert J, Le Morvan V: The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models. Br J Cancer 2009; 101: 350-356.
19. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Dvies P, Boehmer G, van den Akker E, Iftner T: Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8,466 patients. Br J Cancer 2003; 88: 1570-1577. (Pubitemid 36713784)
20. Ricks-Santi L, Mason T, Apprey V, Ahaghotu C, McLauchlin A, et al: p53 Pro72Arg polymorphism and prostate cancer in men of African descent. Prostate, 2010; 70: 1739-1745.
21. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Dahiya AV, Suehiro Y, Tanaka Y, Dahiya R: CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res 2007; 13: 5056-5062. (Pubitemid 47502070)
22. Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, Huang CH: p53 codon 72 and p21 codon polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 2217-2224. (Pubitemid 40054320)
23. Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E, Eiguchi K: Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol 2005; 5: 15.
24. Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS, Giovannucci EL, Hunter DJ: p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 2006; 119: 1836-1868.
25. Tornesello ML, Duraturo ML, Guida V, Losito S, Botti G, Pilotti S, Stefanon B, De Palo G, Buonaguro L, Buonaguro FM: Analysis of TP53 codon 72 polymorphism in HPV-positive and HPV-negative penile carcinoma. Cancer Lett 2008; 269: 159-164.
26. Hughes L, Giri N: Genetic polymorphisms and early-onset prostate cancer: a real potential to personalize prostate cancer screening? Future Oncol 2009; 5: 923-926.
27. Agalliu I, Karlins E, Kwon EM, Iwasaki LM, Diamond A, Ostrander EA, Stanford JL: Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 2007; 97: 826-831. (Pubitemid 47396283)
28. Koutros S, Schumacher FR, Hayes RB, Huang WY, Albanes D, Canzian F, Chanock SJ, Crawford ED, Diver WR, Feigelson HS, Giovanucci E, Haiman CA, Henderson BE, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Le Marchand L, Riboli E, Siddiq A, Stampfer MJ, Stram DO, Thomas G, Travis RC, Thun MJ, Yeager M, Berndt SI: Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res 2010; 70: 2389-2396.
29. Gurumurthy S, Vasudevan KM, Rangnekar VM: Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 2001; 20: 225-243. (Pubitemid 34600970)
30. Collavin L, Lunardi A, Del Sal G: P53-family protein and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 2010; 17: 901-911.
31. Jeong BS, Hu W, Belyi V, Rabadan R, Levine AJ: Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphisms: p53 with arginine at codon favors apoptosis. FASEB J 2010; 24: 1347-1353.
32. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 1996; 56: 3814-3822. (Pubitemid 26272034)
33. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J: Molecular pathology of prostate cancer. J Clin Pathol 2005; 58: 673-684. (Pubitemid 40956818)
34. Massenkeil G, Oberhuber H, Hailemariam S, Sulser T, Diener PA, Bannwart F, Schafer R, Schwarte-Waldhoff I: P53 mutations and loss of heterozygosity on chromosome 8p, 16q, 17p and 18q are confined to advanced prostate cancer. Anticancer Res 1994; 14: 2785-2790.
35. Petersen I, Klein F: HPV in non-gynecological tumors. Pathologe 2008; 29: 118-122.
36. Tu H, Jacobs SC, Mergner WJ, Kyprianou N: Rare incidence of human papillomavirus types 16 and 18 in primary and metastatic human prostate cancer. Urology 1994; 44: 726-731.
37. Wideroff L, Schottenfeld D, Carey TE, Beals T, Fu G, Sakr W, Sarkar F, Schork A, Grossman HB, Shaw MW: Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. Prostate 1996; 28: 117-123. (Pubitemid 26066250)